Recent Company News

• 04:03 AM ET Jun 23, 2025
  

  Ono Pharmaceutical, Vertex Pharmaceuticals to collaborate on povetacicept; terms undisclosed ($440.87, 0.00)

• 08:04 AM ET May 30, 2025
  

  Pfizer reports survival results from Phase 3 BREAKWATER trial of BRAFTOVI combination in mCRC with BRAF V600E mutation ($23.45, 0.00)

• 09:12 AM ET May 28, 2025
  

  Ono Pharmaceutical presents positive results from pivotal phase 2 PROSPECT study of tirabrutinib with relapsed or refractory PCNSL (¥1546.0000, 0)

• 07:01 AM ET May 28, 2025
  

  Bristol Myers Squibb receives European Commission approval for subcutaneous formulation of Opdivo (nivolumab) across multiple solid Tumor indications ($46.89, 0.00)

• 07:03 AM ET May 16, 2025
  

  Bristol Myers Squibb receives EC approval for perioperative regimen of neoadjuvant Opdivo and chemotherapy followed by adjuvant Opdivo for resectable NSCLC with PD-L1 expression ≥1% ($45.81, 0.00)

• 12:03 AM ET May 15, 2025
  

  StreetAccount Summary: Asian stocks reaching new 52-week highs/lows (69 total)

• 11:09 PM ET May 14, 2025
  

  StreetAccount Summary: Japan Stocks reaching new 52-week highs/lows (42 total)

• 11:03 PM ET May 07, 2025
  

  Ono Pharmaceutical reports FY net income attributable ¥50.05B vs FactSet ¥60.31B [10 est, ¥50.10-68.05B] (¥1578.5000, +8.5)

• 10:52 PM ET May 06, 2025
  

  StreetAccount Summary - Trading higher/lower: Japan mid-day

• 03:04 AM ET Apr 28, 2025
  

  Ono Pharmaceutical guides FY net income attributable ¥50.00B vs prior guidance ¥58.00B and FactSet ¥63.51B [10 est, ¥58.50-69.10B] (¥1650.5000, 0)